A Phase 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Explore the Immunogenicity of ID93+GLA-SE Vaccine in BCG-Vaccinated Healthy Adolescent
Latest Information Update: 08 Jul 2021
At a glance
- Drugs ID 93 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- Sponsors Quratis
Most Recent Events
- 22 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 29 May 2019 Status changed from not yet recruiting to recruiting.
- 24 Jan 2019 New trial record